Precision BioSciences Inc. Stock News

Arcus Biosciences (NYSE:RCUS) initiated with an Overweight rating and a $21 (41% upside) price target at Cantor Fitzgerald.Avadel Pharmaceuticals (NASDAQ:AVDL) initiated with a Buy rating and a $14 (9

Most Triangle public companies have seen their market valuations fall in 1Q2020.

Fly Intel: After-Hours Movers PLAY FATE TSLA ZUMZ INCY BBBY PTON CAKE AEHR CHWY DTIL

Adams Chetwood Wealth Management LLC bought a new position in Precision BioSciences Inc (NASDAQ:DTIL) in the 4th quarter, HoldingsChannel.com reports. The fund bought 718,323 shares of the company’s

Since my last article on Allogene Therapeutics about 5 months ago, its share price has fallen by around 30%. I was bearish on the company’s short-term prospects

Sangamo has announced several impressive partnerships with global biotech and big pharma companies. Its recent deal with Biogen gives it ~$700M cash on hand, at

Arcus, a U.S.-based fintech platform, announced on Monday it has formed a partnership with global retail chain 7-Eleven to introduce a suite of payment solution

News is free at Seeking Alpha.This post is a Notable Call. Notable Calls are a Premium feature.To access this and other Notable Calls, try a free trial to Seeking Alpha Premium.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Precision BioSciences, Inc. (NASDAQ:DTIL) missed earnings with its latest yearly results, disappointing...

Celyad is developing both an autologous and allogeneic CAR-T platform to treat both hematological malignancies and solid tumors. Its lead allogeneic product can

Just under a year after its debut on public markets, a Durham gene therapy company says it is positioned – scientifically and financially – for a strong 2020.

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Precision BioSciences (DTIL) today and set a price target of $19.00. The company's

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a

Precision BioSciences, Inc. (DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Ge